We performed a meta-analysis to examine the relationship between risk-reducing salpingo-oophorectomy (RRSO) and breast cancer (BC) risk and mortality. RRSO was associated with a significant reduction in the incidence of BC in women with BRCA1/2 mutations, regardless of history of BC. RRSO could improve the survival of women with BC. Background: Objections have been raised to performing risk-reducing salpingo-oophorectomy (RRSO) to reduce disease incidence and mortality of women with BRCA mutations. We aimed to examine the relationship between RRSO and breast cancer (BC) risk and mortality with a meta-analysis. Materials and Methods: We conducted a comprehensive literature search using the PubMed and Embase databases for literature published from these databases' creation to September 2017. Hazard ratio (HR) estimates were identified directly from the original articles. Pooled results were calculated on the basis of nonoverlapping studies by fixed-effect meta-analysis. Results: RRSO was associated with a significant reduction in the incidence of BC in women with BRCA1/2 mutations who had no history of BC (HR ¼ 0.58; 95% confidence interval [CI], 0.37 to 0.78). Even in women with a history of BC, RRSO could reduce the risk of recurrence (HR ¼ 0.50; 95% CI, 0.31 to 0.69). We further found that publication year was a critical interaction factor from a corresponding subgroup analyses in BC risk (P heterogeneity ¼ .024). In addition, we found that RRSO could improve the survival of women with BC (HR ¼ 0.33; 95% CI, 0.28 to 0.38). Conclusion: Summary estimates presented here indicate that RRSO was closely related to the reduced risk of BC caused by BRCA mutations, but publication year was a critical interaction factor and it should be noted that more recent studies have failed to find a significant reduction in BC risk associated with RRSO.
Introduction
Breast cancer (BC) is one of the most common cancer diseases in women. 1, 2 Ten percent to 20% of women diagnosed with advanced BC have a poor survival rate. 3 The BRCA1 or BRCA mutation increase the risk of BC by 50% to 80%. [4] [5] [6] Risk-reducing surgery has been proposed to improve the survival of BC patients or to prevent BC incidence for subjects who once were clinically identified as having a BRCA gene mutation by DNA direct sequencing or family history. Meanwhile, many studies have been conducted on whether risk-reducing salpingooophorectomy (RRSO), one of the most common risk-reducing surgeries, could reduce the risk of BC in women with BRCA gene mutation.
In a recent meta-analysis, Li et al 7 suggested that RRSO can reduce the risk of BC to 45% in women who have BRCA mutations and who have no history of BC. In the PROSE study, a large multicenter cohort study, women with BRCA gene mutation who underwent RRSO had a significantly lower BC risk in 50% compared to those who did not receive RRSO, a finding comparable to previous studies. 8 Nevertheless, Kotsopoulos et al 9 suggested that no significant statistical relationship could be found between RRSO and survival outcomes among patients with BRCA mutations in what is to date the largest prospective analysis. Likewise, Heemskerk-Gerritsen et al 10 obtained results indicating that there were no significant associations between RRSO and BC risk. All the women in these studies had no history of BC, but the last 2 studies had findings different from the first 2, which may be related to sample size, type of gene mutation, or proportion of RRSO patients. All in all, we observed that RRSO had a greater significance for women with a history of BC and women with the BRCA1 mutation.
The same disagreements also exist between RRSO and BC mortality. So far, most studies have shown that women who receive RRSO have significantly improved survival, but some researchers have also observed that the results were different according to different genotypes. Domchek et al 11 and Metcalfe et al 12 indicated
that RRSO was more helpful for women with BRCA1-positive disease and had no protective effect for women with BRCA2-positive disease. However, this difference was not observed in the study of Finch et al. 13 The impact of genotype on mortality of BC after patients undergo RRSO thus needs to be further explored. Li et al 7 concluded that RRSO reduced all-cause mortality for women without a history of BC, with a rate of 23% compared to 34% of those with a history of BC before RRSO. In line with this, Domchek et al 11 reported that there was a statistically significant reduction in BC-specific mortality if RRSO was performed on women with a history of BC. It thus seems likely that a history of BC before RRSO is a factor affecting BC mortality. Therefore, in order to explore the relationships between a history of BC and type of mutation with, respectively, the incidence and mortality of BC, we carried out a systematic review that assessed 13 years' worth of related research. We found several articles that suggested that RRSO is not exactly significant in terms of BC risk and mortality.
Materials and Methods

Search Strategy
This systematic review and meta-analysis was reported and carried out according to the PRISMA guidelines. 14 We conducted a comprehensive electronic literature search on the Medline (via PubMed) and Embase (via Embase) databases using the search terms "BRCA1," "BRCA2," "oophorectomy," and "breast cancer," updated to November 26, 2017 . Details are listed in Supplemental Table 1 in the online version. We also manually reviewed the references lists of previous reviews for relevant articles. Only studies written in the English language were included in this meta-analysis. We did not attempt to obtain any unpublished studies. Any disagreement regarding study inclusion was resolved by discussion.
All procedures performed in studies involving human participants were in accordance with the ethical standards of institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or with comparable ethical standards. Informed consent was obtained from all individual participants included in the studies we analyzed.
Study Selection
Two investigators (Y.L.X. and K.W.) independently screened titles and abstracts of the identified articles to assess eligibility. Then the 2 investigators independently evaluated the articles after reviewing the full text. When two or more publications were of the same study, those with the larger sample and more detailed data were adopted. Any inconsistencies were resolved by further discussion.
Articles were included in our study if they fulfilled all of the following criteria: (1) Both the case and control subjects were women who had BRCA1 or BRCA2 mutations, regardless of history of BC before surgery. (2) The case subjects were treated with prophylactic surgeries, including oophorectomy and salpingooophorectomy. ( 3) The control subjects were women who did not undergo these surgeries. (4) BC risk or mortality due to prophylactic surgeries for women with and without a history of BC, and hazard ratio (HR) values were provided. (5) Study type was a cohort study or a caseecontrol study.
Data Extraction and Quality Assessment
Data extraction was implemented independently by one investigator (Y.L.X.), and then its accuracy was checked by another investigator (K.W.). Any inconsistency was resolved by discussion. The following information was extracted from each study: first author's family name, year of publication, data source, type of study, mean follow-up duration, mean age at diagnosis BC, history of BC (sample size), number of each mutation type, exposure or interventional variables, BC cases, mortality cases, HRs and/or odds ratios (ORs) and 95% confidence intervals (CIs) of BC risk, HRs and/or ORs and 95% CIs of mortality, and adjustment factors.
We used the Newcastle-Ottawa quality assessment scale to evaluate each study's quality. 15 Quality assessment included 3 aspects, including selection, comparability, and outcome. A study could get a maximum of 1 star for each point. Only 9 stars could be obtained at the highest level of each study. We considered a study with more than 7 stars to be a high-quality study, and 7 or fewer stars indicated low-quality research.
Statistical Analysis
We conducted a meta-analysis of patients with and without a history of BC, respectively, and performed subgroup analyses of women who had different BRCA subtypes (BRCA1 mutation group, BRCA2 mutation group, and group with both, denoted BRCA1/2). We calculated the pooled effect size for each outcome (BC risk and mortality) along with the corresponding 95% CI. HR was adopted to assess the relationship between oophorectomy (or salpingooophorectomy), and the BC risk and survival of BC cases. OR and relative risk were considered as equivalent to HR simultaneously when the incidence of BC or the death rate was < 20%. [16] [17] [18] We calculated the overall effect estimation of all dichotomous data as the risk ratio with 95% CI.
Statistical heterogeneity among studies was evaluated by Q statistics. Here, we used P heterogeneity (qualitative analysis) and I 2 (quantitative analysis) to reflect the heterogeneity between studies. When P heterogeneity > .10, we chose the fixed effect model. When P heterogeneity .10, heterogeneity would be analyzed and processed first. If the heterogeneity still cannot be eliminated, we would choose the random-effect model. The larger the I 2 value, the greater the heterogeneity between the studies. In general, heterogeneity is classified as low, medium, and high by 25%, 50%, and 75%. To assess the possibility of publication bias, we used the Begg rank correlation test. All analyses were conducted by Stata/SE software 12.0 (StataCorp, College Station, TX). All statistical tests were 2 sided. P < .05 was considered statistically significant.
Results
Literature Search and Study Characteristics
The process and results of the literature search are shown in Figure 1 . The search yielded 1093 studies, 580 from the PubMed database and 513 from the Embase database, between July 1994 and October 2017. After excluding 185 duplicates, we obtained 82 potentially relevant studies by screening titles and abstracts. We excluded 65 studies that did not conform to our standards after browsing full text. Detailed reasons for exclusion are listed in Supplemental Table 2 in the online version. When we reviewed the reference lists of prior reviews, we discovered 2 additional studies that were in line with the inclusion criteria. In the end we had 19 studies, the characteristics and details of which are listed in Tables 1  and 2 .
The study included 9 prospective cohort studies, 9,11,13,19-23,28 9 retrospective cohort studies, 10, 12, [16] [17] [18] [24] [25] [26] 29 and 1 caseecontrol study. 27 Eight of these studies were from Europe, including countries such as the United Kingdom and the Netherlands. 10, 18, 19, 21, 25, 26, 28, 29 Six studies were from the United States. 9, 12, 16, 17, 20, 24 The remaining 9 studies were international cooperative studies. Including exposed and nonexposed (surgery or nonsurgery) populations, the sample size ranged from 36 to 3722. The mean or median follow-up time ranged from 2.6 to 16.5 years.
The methods of determining surgical exposure varied from study to study. Most studies used questionnaires to interview or mail participants; medical records were also used. Sixteen studies had ! 7 stars, indicating that the quality of the included studies was generally good (Supplemental Table 3 in the online version). 
RRSO and BC Risk
Fourteen studies explored the relationship between RRSO and BC risk (Table 1) . [9] [10] [11] 16, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] In these studies, patients in 8 studies had no history of BC before surgery [9] [10] [11] 16, [19] [20] [21] 27 and patients from 5 studies had a history of BC. 11, 17, 19, 24, 25 Both populations were discussed in 2 studies: Domchek et al 11 and Mavaddat et al. 19 Three other studies did not distinguish whether the population had a history of BC. 22, 23, 26 Eight studies showed that a population with no history of BC before RRSO was associated with a reduced risk of BC in BRCA1/2 carriers (HR ¼ 0.58; 95% CI, 0.37 to 0.78), but a moderate heterogeneity (I 2 ¼ 69.2%, P heterogeneity ¼ .002, n ¼ 8) was explored. Table 3 ).
In the process of studying the relationship between BC risk and RRSO, we found that 3 studies addressing this issue did not indicate whether the population had a history of BC before surgery. 22, 23, 26 We combined the results of these 3 studies and found that RRSO also can reduce BC risk in this population (HR ¼ 0.59; 95% CI, 0.45 to 0.74), and no heterogeneity was found (I 2 ¼ 0.0%,
. We did not analyze the genetic subgroups of this population because there were too few studies (Table 3 ). In addition, 4 studies summarized the impact of age at RRSO on the risk of BC. 10, 11, 26, 27 Although no statistically significant differences were found between age > 50 years and age < 50 years groups (P ¼ .212), analysis of data revealed that RRSO had a trend of benefit for BRCA carriers who were < 50 (HR ¼ 0.45; 95% CI, 0.24 to 0.67) (Table 3) . Finally, we conducted a subgroup analysis of related studies according to the year of publication. [9] [10] [11] 16, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] We divided the studies into 3 groups (<2010; 2010-2015, >2015) and found that the earliest studies found that RRSO had protective benefits for BRCA carriers (For studies published before 2010, HR ¼ 0.43; 95% CI, 0.31 to 0.54, n ¼ 7; For studies published between 2010 and 2015, HR ¼ 0.58; 95% CI, 0.47 to 0.69, n ¼ 6). 11, 17, [19] [20] [21] [22] [23] [24] [25] [26] [27] However, the most recent 3 studies had opposite results (HR ¼ 0.96; 95% CI, 0.65 to 1.26, n ¼ 3). 9, 10, 16 This finding was statistically significant (P ¼ .024) ( Table 3) . Figure 2 provides a meta-analysis and Figure 3 a subgroup analysis of RRSO and BC risk in different populations. 
Other Subgroup Analysis
We also conducted statistical analysis of the follow-up time, sample size, geographic area, and surgical approach of each study, but no statistically significant differences were found (Table 3) .
Publication Bias
We found no evidence of publication bias in any analyses using the Begg or Egger tests (all P > .05).
Discussion
To our knowledge, this is the most comprehensive and largest study to systematically investigate RRSO in BRCA1/2 mutation carriers with BC. We have summarized the evidence for RRSO in BC risk and mortality in women with BRCA1/2 mutations.
In our study, RRSO was associated with a 42% lower risk of BC in women with BRCA1/2 mutations and no history of BC. Although there was no statistically significant difference between the 2 subgroups, the postoperative effect of the BRCA1 mutation on Table 3 Continued In publication, researchers observed first incidence of BC in women without history of BC and recurrence of BC in women with history of BC. At this time, they would be regarded as 2 studies.
c
We only included population from Europe or Americas, excluded population from both Americas and Europe, or other regions.
d
Study did not explicitly mention whether RRSO was bilateral or unilateral.
e Data were that of all study members included in this group.
f Population in this part of study did not explain whether there was history of BC before RRSO.
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women was superior to that of women with the BRCA2 mutation. RRSO also had a protective effect on women with preoperative BC, reducing the risk of recurrence by about 50%. Most of the early studies found that RRSO could reduce the incidence of BC. 11, 17, [19] [20] [21] 27 A study by Domchek et al 11 mentioned that RRSO was associated with a reduced risk of BC in women with no history of BC, and there were no significant differences between BRCA1 and BRCA2 mutation carriers. In addition, Li et al 7 found that in BRCA1 mutation carriers with no history of BC, RRSO had an age-related risk of reducing BC risk before the age of 50, but no protective effect after the age of 50. More recent studies, however, do not have results consistent with this. 9, 10, 16 The study of Kotsopoulos et al 9 was the largest prospective analysis of BC risk after RRSO in women with BRCA1 or BRCA2 mutations. During follow-up, 350 of 3722 women with undiagnosed BRCA1/2 mutation ended up with BC, with an average follow-up time of 5.6 years. Finally, they found no statistically significant association between RRSO and BC risk, whether they had BRCA1 or BRCA2 mutations (after adjusting for age). However, they added in their stratified analysis that RRSO only reduces the risk of BC in BRCA2 mutation carriers younger than 50 years of age (after adjusting for age). Similarly, in a retrospective study by Heemskerk-Gerritsen et al, 10 89 cases of BC were ultimately found in 822 women with no history of BC, with a median follow-up of 3.2 years; nor was there a statistically significant association between RRSO and BC risk.
Other than that, we found that in women without a history of BC, RRSO could reduce all-cause mortality by approximately 73%. Further, the risk of BRCA1 carriers was significantly reduced, although insufficient data regarding BRCA2 meant valid results could not be obtained. For women who had preoperative BC, the postoperative all-cause mortality rate was lower than that of women without a history of BC, which was a decrease of 67%. There were no statistically significant differences between the 2 subgroups (BRCA1 69% and BRCA2 64%) (P ¼ .730). Finally, we concluded that RRSO could reduce the all-cause mortality rate before or after 
Analyses of (C) RRSO and (D) BC Risk in Patients With History of BC. Subgroup Analyses of (E) Age at RRSO and (F) BC Risk
Abbreviations: BC ¼ breast cancer; RRSO ¼ risk-reducing salpingo-oophorectomy.
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Many studies reported that RRSO can reduce patient mortality. In the study of Finch et al, 13 with an average follow-up of 5.6 years, with 68 deaths in 5783 subjects, RRSO had reduced all-cause mortality for 77% of women with no history of BC who were under the age of 70, and they had a 68% reduction with a history of BC. Domchek et al 11 reached similar conclusions, but they also further explored the relationship between overall survival rate and RRSO performed on subjects at different ages. They found no overall difference in all-cause mortality between groups under age 50 and those over 50. However, Metcalfe et al 12 suggested that people over 50 could not benefit from RRSO. They also stratified BRCA gene according to mutations types, and concluded that RRSO did not reduce the all-cause mortality of BRCA2 carriers with a history of BC. Domchek et al 11 not only drew the same conclusion but also found that RRSO did not reduce the BC-specific mortality rate of BC in BRCA2 carriers. There are several reasons for these differences. In the studies we included, Kotsopoulos et al 9 and Heemskerk-Gerritsen et al 10 suggested that RRSO does not reduce BC risk, contrary to the findings of many earlier studies. We observed that the population included in Kotsopoulos et al 9 were all BRCA1/2 mutation carriers who did not have a history of BC, whereas in the early part of the study women in the cohort had mixed BC history. First of all, the risk of recurrence in this subset of women was higher than that of women who had never had BC. Second, women with a history of BC were more likely to choose preventive surgical treatment than women without BC. Therefore, in the study involving women with a history of BC, the incidence of BC (ipsilateral recurrence and contralateral occurrence) and the surgical rate of RRSO were higher, so there was a certain bias. In addition, the study by Kotsopoulos et al 9 was the largest study (n ¼ 3722) with regard to the direction of this research, and the number of final events was the highest in the same study so far (n ¼ 350). Early studies of the same kind were subject to many limitations, with small sample sizes and short follow-up times. Therefore, there was bound to be an error compared to the study by Kotsopoulos et al. Further, Heemskerk-Gerritsen et al 10 noted that RRSO resulting in a decreased BC risk in BRCA1/2 mutant carriers in the prior study could be caused by some bias. They found that some women had a history of undergoing risk-reducing mastectomy (RRM) before RRSO in some of the earlier studies, which caused a certain bias. On the one hand, the implementation of RRM had caused a difference on the observation time of the RRSO and non-RRSO groups; in particular, the observation time of non-RRSO was On the other hand, the majority of women in the non-RRSO group were young; they had not yet had children, and/ or they had not reached the age at which RRSO is recommended by the Netherlands (35-40 years old for BRCA1 mutation carriers and 40-45 years old for BRCA2 mutation carriers). Therefore, this population of young women may prefer RRM, which differs from the group without RRSO or RRM. Interestingly, we divided the related studies into 3 subgroups according to the study's publication year, and corresponding subgroup analyses in BC risk (P heterogeneity ¼ .024) indicated that publication year was a critical interaction factor. A significant time trend in decreased BC prevention benefits of RRSO for patients with BRCA1/2 mutation may be due to increases in hormone replacement therapies. We also observed differences in the incidence and survival of BC with different BRCA subtype mutations. Mavaddat et al 30 had suggested that this problem might be explained by the pathology and etiology of BRCA1/2-related BC. Earlier studies had reported that estrogen receptor (ER) and progesterone receptor were mostly negative in BRCA1 mutation carriers, while ER and progesterone receptor in BRCA2 mutation-related tumors tended to be positive, and may be more sensitive to hormone stimulation. 30, 31 Kotsopoulos et al 9 conducted a statistical analysis of hormone receptor for 
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77% of the population and found that the ratio of BRCA1 carriers to ER-positive BC was 27%, while that of BRCA2 carriers was up to 80%. Finally, they concluded that RRSO had a strong protective effect on premenopausal/ER-positive BC in women with BRCA2 mutation. From a biological point of view, this may be due to differences in endogenous levels of estrogen and progesterone caused by RRSO, which reduces the occurrence of hormone-related tumors. Some reports highlighted the importance of RRSO at an optimal age, and suggested that RRSO was associated with increased mortality in women over 45 years of age, especially if no sequential hormone therapy was provided. 32, 33 In fact, this point may be related to the age at which the annual rate of ovarian cancer begins to rise. 13 Although the ages of the different research stratification groupings were slightly different, the trend was consistent. The Women's Health Initiative in postmenopausal women does not show cardiovascular benefits from hormone therapy after RRSO, but young women may benefit from natural menopause. 34, 35 Rebbeck et al 8 surveyed 462 patients and reported that hormone therapy after RRSO did not increase the risk of BC. Eisen et al 27 provided hormone therapy to women who had received RRSO and did not observe an increased risk associated with hormone therapy. However, a longer-term study is required on this important issue. The present study had several limitations. First, few studies exist on RRSO and the incidence and survival of BC. In our study of 19 articles, after removing 9 prospective cohort studies, there were only 9 retrospective cohort studies and 1 caseecontrol study, which made ORs and relative risks difficult to analyze. Even though the incidence of BC in BRCA1/2 carriers was less than 2% to 4%, we consider it to be the same as the HRs, but it still had a margin of error. Second, we tried to extract the HRs from studies as associated factors in the statistical process to ensure relative reliability. However, as a result of different adjustments for potential confounding variables adopted in different studies, the inconsistency of such adjustments further limit the comparability of the studies and may lead to different degrees of confusion. Third, we retained only the 19 best studies left after screening the sources of the study population, but there were still a few unavoidable overlaps in the individual study populations. For example, the PROSE database and the HEBOH database had several identical data sources; and the PROSE database incorporated new data sources (institutions) continuously over time, which resulted in statistically inaccurate results. Fourth, in most of the research we incorporated, there was uneven sampling of BRCA1 and BRCA2 gene mutation carriers, and a small sample size of BRCA2 carriers in some studies led to unreliable results. Fifth, in the early days, the range of surgical resections and detailed pathologic evaluations recommended by various institutions were not uniform, which results in certain differences between studies in the same field and in different periods. That may lead to statistical errors. Sixth, there was a certain distance between the sample size of the included study (minimum of only 98) and follow-up time (2.6-16.5 years). The insufficient follow-up time made it impossible to observe the benefits of RRSO on the survival of patients. Even if we detected differences in the results of the analysis, the lack of follow-up time may still be statistically ineffective. Therefore, in order to obtain more real-world data, it is better to obtain a larger sample size and a longer follow-up. Finally, in the population included in the original studies, there was a potential selection bias between patients receiving and not receiving RRSO, which may affect the conclusions. However, because we had limited access to the initial data, we could not assess the baseline characteristics of both groups. Generally speaking, although a metaanalysis cannot completely avoid some of the shortcomings of the original study, it may still be used to arrive at more reliable conclusions than can be drawn by a single study.
Conclusion
On the basis of the summary of existing studies, we conclude that RRSO is strongly associated with a reduced risk of BC, and publication year was a critical interaction factor. In addition, RRSO can also reduce the mortality of BC patients with BRCA mutations to some extent. We still need more high-quality studies in future research. Large sample size, long follow-up, and clear basic information were obtained to perform an adequate meta-analysis of risk and mortality.
Clinical Practice Points
Disagreements exist between RRSO and BC incidence and mortality. RRSO was associated with a significant reduction in the incidence of BC in women with BRCA1/2 mutations, regardless of history of BC. In addition, we found that RRSO could improve the survival of women with BC. Continuing efforts to identify a promising subset of women with BRCA1/2 mutations receiving RRSO should be made in further clinical trials.
